Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform that focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs. The platform not only offers standard disease model development services but is also skilled in customizing complex disease models to meet the diverse research needs of clients. In addition, the platform provides a full range of services from drug screening and efficacy evaluation to safety assessment, helping clients accelerate the new drug development process.
- With the advent of the era of precision medicine and the deepening understanding of disease mechanisms, large animal models such as non-human primates, dogs, rabbits, and miniature pigs have shown unique advantages and value in key areas of drug development. Due to their higher physiological similarity to humans, these models are particularly valuable in the research of cardiovascular diseases, metabolic disorders, inflammatory immune diseases, and neurological diseases.In order to assist clients in precisely selecting suitable large animal models, Medicilon has established an innovative, flexible, and reliable Large Animal Pharmacodynamic Research Service Platform. This platform focuses on large animal models such as non-human primates, dogs, rabbits, and miniature pigs, and offers comprehensive and in-depth disease model development and pharmacodynamic research. The platform is equipped with world-class experimental facilities and equipments and is supported by a team of experienced scientists and technical experts. This professional team is dedicated to providing pharmacodynamic research services, including experimental protocal design, model establishment, and data analysis, to accelerate the translation of scientific research results into clinical applications.
Diverse Disease Models, Empowering Drug Development Innovation
- The Medicilon Large Animal Pharmacodynamic Research Service Platform encompasses a wide range of disease models, including but not limited to metabolic diseases (such as obesity, diabetes, and hyperuricemia), cardiovascular diseases (such as thrombosis, stroke, and atherosclerosis), inflammatory and immune diseases (such as arthritis, osteoporosis, and psoriasis), as well as other disease models. This comprehensive coverage addresses nearly all major disease areas in current drug development.Table 1: Types of Large Animal Pharmacodynamic Models Conducted by Medicilon
AAALAC Certification, Animal Facilities Meet International Standards
- Medicilon's preclinical animal testing facility has been accredited by AAALAC International since 2009 and has consistently passed re-evaluations. The facility meets international standards in experimental animal quality, animal welfare, and biosafety.Table 2: Current Large Animal Capacity at MedicilonMedicilon's large animal efficacy research and development service platform currently boasts spacious animal housing. From animal care and management to experimental procedures, every step strictly adheres to international standards, providing a solid foundation for large-scale, high-quality, and efficient efficacy experiments.
Advanced Instruments and Equipment Enhance R&D Efficiency and Effectiveness
- The platform is equipped with advanced large animal experimental instruments, pharmacodynamic experimental analysis equipment, and pharmacodynamic experimental pathological research devices, providing strong technical support for disease efficacy evaluation and ensuring the accuracy and reliability of the experimental process.1. Large Animal Experimental Instruments and Equipment2. Pharmacodynamic Experimental Analysis Equipment3. Pharmacodynamic Experimental Pathological Research Equipment
- In the ever-evolving wave of the biopharmaceutical field, Medicilon's large animal efficacy research and development service platform adheres to the principles of innovation leadership, openness, and collaborative win-win strategies. The platform continuously deepens the expansion of its functions and service boundaries. The platform will actively explore new methods and technologies for constructing disease models, continuously enriching and developing models for neurological disorders, inflammatory and immune diseases, cardiovascular and metabolic disorders, digestive system diseases, ocular diseases, and other conditions. This aims to provide clients with more precise, efficient, and comprehensive drug development solutions.
评论
发表评论